166 related articles for article (PubMed ID: 17041888)
1. Cotreatment with a novel phosphoinositide analogue inhibitor and carmustine enhances chemotherapeutic efficacy by attenuating AKT activity in gliomas.
Van Meter TE; Broaddus WC; Cash D; Fillmore H
Cancer; 2006 Nov; 107(10):2446-54. PubMed ID: 17041888
[TBL] [Abstract][Full Text] [Related]
2. Synergistic augmentation of antimicrotubule agent-induced cytotoxicity by a phosphoinositide 3-kinase inhibitor in human malignant glioma cells.
Shingu T; Yamada K; Hara N; Moritake K; Osago H; Terashima M; Uemura T; Yamasaki T; Tsuchiya M
Cancer Res; 2003 Jul; 63(14):4044-7. PubMed ID: 12874004
[TBL] [Abstract][Full Text] [Related]
3. Potentiation of paclitaxel cytotoxicity in lung and esophageal cancer cells by pharmacologic inhibition of the phosphoinositide 3-kinase/protein kinase B (Akt)-mediated signaling pathway.
Nguyen DM; Chen GA; Reddy R; Tsai W; Schrump WD; Cole G; Schrump DS
J Thorac Cardiovasc Surg; 2004 Feb; 127(2):365-75. PubMed ID: 14762343
[TBL] [Abstract][Full Text] [Related]
4. Synergistic augmentation of rapamycin-induced autophagy in malignant glioma cells by phosphatidylinositol 3-kinase/protein kinase B inhibitors.
Takeuchi H; Kondo Y; Fujiwara K; Kanzawa T; Aoki H; Mills GB; Kondo S
Cancer Res; 2005 Apr; 65(8):3336-46. PubMed ID: 15833867
[TBL] [Abstract][Full Text] [Related]
5. Phosphoinositide-3-kinase inhibition enhances radiosensitization of cervical cancer in vivo.
Liu Y; Cui B; Qiao Y; Zhang Y; Tian Y; Jiang J; Ma D; Kong B
Int J Gynecol Cancer; 2011 Jan; 21(1):100-5. PubMed ID: 21330835
[TBL] [Abstract][Full Text] [Related]
6. Phosphatidylinositol 3-kinases inhibitor LY294002 potentiates the cytotoxic effects of doxorubicin, vincristine, and etoposide in a panel of cancer cell lines.
Badinloo M; Esmaeili-Mahani S
Fundam Clin Pharmacol; 2014 Aug; 28(4):414-22. PubMed ID: 23837575
[TBL] [Abstract][Full Text] [Related]
7. Synergistic interaction between 17-AAG and phosphatidylinositol 3-kinase inhibition in human malignant glioma cells.
Premkumar DR; Arnold B; Jane EP; Pollack IF
Mol Carcinog; 2006 Jan; 45(1):47-59. PubMed ID: 16267832
[TBL] [Abstract][Full Text] [Related]
8. A new selective AKT pharmacological inhibitor reduces resistance to chemotherapeutic drugs, TRAIL, all-trans-retinoic acid, and ionizing radiation of human leukemia cells.
Martelli AM; Tazzari PL; Tabellini G; Bortul R; Billi AM; Manzoli L; Ruggeri A; Conte R; Cocco L
Leukemia; 2003 Sep; 17(9):1794-805. PubMed ID: 12970779
[TBL] [Abstract][Full Text] [Related]
9. Modulating effect of the PI3-kinase inhibitor LY294002 on cisplatin in human pancreatic cancer cells.
Fujiwara M; Izuishi K; Sano T; Hossain MA; Kimura S; Masaki T; Suzuki Y
J Exp Clin Cancer Res; 2008 Nov; 27(1):76. PubMed ID: 19032736
[TBL] [Abstract][Full Text] [Related]
10. Radiation sensitization of human cancer cells in vivo by inhibiting the activity of PI3K using LY294002.
Gupta AK; Cerniglia GJ; Mick R; Ahmed MS; Bakanauskas VJ; Muschel RJ; McKenna WG
Int J Radiat Oncol Biol Phys; 2003 Jul; 56(3):846-53. PubMed ID: 12788194
[TBL] [Abstract][Full Text] [Related]
11. The lethal effects of pharmacological cyclin-dependent kinase inhibitors in human leukemia cells proceed through a phosphatidylinositol 3-kinase/Akt-dependent process.
Yu C; Rahmani M; Dai Y; Conrad D; Krystal G; Dent P; Grant S
Cancer Res; 2003 Apr; 63(8):1822-33. PubMed ID: 12702569
[TBL] [Abstract][Full Text] [Related]
12. Combinatorial therapy with adenoviral-mediated PTEN and a PI3K inhibitor suppresses malignant glioma cell growth in vitro and in vivo by regulating the PI3K/AKT signaling pathway.
Nan Y; Guo L; Song Y; Wang L; Yu K; Huang Q; Zhong Y
J Cancer Res Clin Oncol; 2017 Aug; 143(8):1477-1487. PubMed ID: 28401302
[TBL] [Abstract][Full Text] [Related]
13. Akt/protein kinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation.
Brognard J; Clark AS; Ni Y; Dennis PA
Cancer Res; 2001 May; 61(10):3986-97. PubMed ID: 11358816
[TBL] [Abstract][Full Text] [Related]
14. The epidermal growth factor receptor pathway mediates resistance to sequential administration of radiation and chemotherapy in primary human glioblastoma cells in a RAS-dependent manner.
Chakravarti A; Chakladar A; Delaney MA; Latham DE; Loeffler JS
Cancer Res; 2002 Aug; 62(15):4307-15. PubMed ID: 12154034
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway but not the MEK/ERK pathway attenuates laminin-mediated small cell lung cancer cellular survival and resistance to imatinib mesylate or chemotherapy.
Tsurutani J; West KA; Sayyah J; Gills JJ; Dennis PA
Cancer Res; 2005 Sep; 65(18):8423-32. PubMed ID: 16166321
[TBL] [Abstract][Full Text] [Related]
16. Regulation of cellular growth, apoptosis, and Akt activity in human U251 glioma cells by a combination of cisplatin with CRM197.
Wang L; Wang P; Liu Y; Xue Y
Anticancer Drugs; 2012 Jan; 23(1):81-9. PubMed ID: 21934602
[TBL] [Abstract][Full Text] [Related]
17. Autocrine signaling through Ras regulates cell survival activity in human glioma cells: potential cross-talk between Ras and the phosphatidylinositol 3-kinase-Akt pathway.
Sakata K; Kato S; Fox JC; Shigemori M; Morimatsu M
J Neuropathol Exp Neurol; 2002 Nov; 61(11):975-83. PubMed ID: 12430714
[TBL] [Abstract][Full Text] [Related]
18. PI3K/Akt inhibitor LY294002 potentiates homoharringtonine antimyeloma activity in myeloma cells adhered to stromal cells and in SCID mouse xenograft.
Chen P; Wen X; Wang B; Hou D; Zou H; Yuan Q; Yang H; Xie J; Huang H
Ann Hematol; 2018 May; 97(5):865-875. PubMed ID: 29450644
[TBL] [Abstract][Full Text] [Related]
19. Oxidant-mediated Akt activation in human RPE cells.
Yang P; Peairs JJ; Tano R; Jaffe GJ
Invest Ophthalmol Vis Sci; 2006 Oct; 47(10):4598-606. PubMed ID: 17003457
[TBL] [Abstract][Full Text] [Related]
20. Migrating glioma cells activate the PI3-K pathway and display decreased susceptibility to apoptosis.
Joy AM; Beaudry CE; Tran NL; Ponce FA; Holz DR; Demuth T; Berens ME
J Cell Sci; 2003 Nov; 116(Pt 21):4409-17. PubMed ID: 13130092
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]